[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630595":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":11,"studyPopulation":11,"armGroups":31,"interventions":37,"overallOfficials":11,"centralContacts":41,"locations":47,"responsibleParty":66,"collaborators":11,"id":68,"slug":11,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":11,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"ORR assessed by IRC according to RECIST v1.1 s）",null,"once every 6 weeks, estimated 2 years",[14,16,18,20,23],{"measure":15,"description":11,"timeFrame":12},"Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1;",{"measure":17,"description":11,"timeFrame":12},"Disease Control Rate (DCR) assessed by the IRC and investigator according to RECIST v1.1;",{"measure":19,"description":11,"timeFrame":12},"Duration of Response (DoR) assessed by the IRC and investigator according to RECIST v1.1;",{"measure":21,"description":11,"timeFrame":22},"Progression-Free Survival (PFS) assessed by the IRC and investigator according to RECIST v1.1;","Estimated 2 years",{"measure":24,"description":11,"timeFrame":22},"Overall Survival (OS).",{"allocation":26,"interventionModel":27,"interventionModelDescription":11,"primaryPurpose":28,"observationalModel":11,"timePerspective":11,"maskingInfo":29},"NA","SINGLE_GROUP","TREATMENT",{"masking":30,"maskingDescription":11,"whoMasked":11},"NONE",[32],{"label":33,"type":34,"description":11,"interventionNames":35},"SHR-1826","EXPERIMENTAL",[36],"Drug: SHR-1826",[38],{"type":39,"name":33,"description":33,"armGroupLabels":40,"otherNames":11},"DRUG",[33],[42],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},"Yijun Jia","CONTACT","+0518-81220121","Yijun.jia@hengrui.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Affiliated Cancer Hospital of Shandong First Medical University","RECRUITING","Jinan","Shandong","250117","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.99722,36.66833,{"lat":60,"lon":59},[63],{"name":64,"role":65,"phone":11,"phoneExt":11,"email":11},"Jinming Yu","PRINCIPAL_INVESTIGATOR",{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100630595",false,"NCT07489716","A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years\n2. ECOG performance status score of 0 or 1;\n3. Histopathologically confirmed advanced or metastatic non-small cell lung cancer;\n4. Participants must provide archived or fresh tumor tissue;\n5. Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease;\n6. At least one measurable lesion according to RECIST v1.1 criteria;\n7. Expected survival ≥3 months;\n8. Adequate organ function;\n\nExclusion Criteria:\n\n1. Central nervous system metastasis or meningeal metastasis with clinical symptoms\n2. History of or concurrent other malignancies;\n3. Untreated spinal cord compression ;\n4. Uncontrolled tumor-related pain;\n5. Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1;\n6. History of interstitial lung disease;\n7. Severe cardiovascular\u002Fcerebrovascular diseases;","ALL","18 Years","75 Years",{"count":78,"type":79},90,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.",[85],"Non-Small Cell Lung Cancer","2026-05-12",{"date":88,"type":89},"2026-05-13","ACTUAL",{"date":91,"type":89},"2026-04-29",{"date":93,"type":79},"2028-12",{"name":5,"class":6},1]